FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083606656> ?p ?o ?g. }

• W2083606656 endingPage "2086" @default.
• W2083606656 startingPage "2076" @default.
• W2083606656 abstract "HomeCirculationVol. 115, No. 15Molecular Magnetic Resonance Imaging in Cardiovascular Medicine Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBMolecular Magnetic Resonance Imaging in Cardiovascular Medicine David E. Sosnovik, MD, Matthias Nahrendorf, MD and Ralph Weissleder, MD, PhD David E. SosnovikDavid E. Sosnovik From the Center for Molecular Imaging Research (D.E.S., M.N., R.W.) and the Department of Cardiology (D.E.S.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass. Search for more papers by this author , Matthias NahrendorfMatthias Nahrendorf From the Center for Molecular Imaging Research (D.E.S., M.N., R.W.) and the Department of Cardiology (D.E.S.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass. Search for more papers by this author and Ralph WeisslederRalph Weissleder From the Center for Molecular Imaging Research (D.E.S., M.N., R.W.) and the Department of Cardiology (D.E.S.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass. Search for more papers by this author Originally published17 Apr 2007https://doi.org/10.1161/CIRCULATIONAHA.106.658930Circulation. 2007;115:2076–2086The ability of magnetic resonance imaging (MRI) to evaluate cardiovascular pathophysiology at several levels is one of the strengths of the technique. As shown in Figure 1, cardiac phenotype can be assessed at the whole-organ level by cine MRI, at the regional level with strain, perfusion, and viability imaging, and at the metabolic level with spectroscopic techniques.1,2 However, MRI of biological processes at the cellular and subcellular level (molecular MRI) has been studied most extensively in other disease states such as cancer.3,4 Molecular MRI techniques are, however, being increasingly developed for cardiovascular applications and, if fully developed, have the potential to make a significant impact on the practice of cardiovascular medicine. Download figureDownload PowerPointFigure 1. Comprehensive analysis of cardiac phenotype by MRI. A, cine MRI of a mouse heart; B, area of myocardial infarction delineated by delayed enhancement MRI in a mouse heart; C, corresponding triphenyltetrazolium (TTC) image. D, map of myocardial perfusion (ml/g per min) in a mouse heart obtained with a spin labeling technique;1 E, strain rate imaging at the midventricular level in a wild-type mouse;1 F, a phosphocreatine metabolite map in an isolated perfused rat heart fused with the corresponding coronary angiogram.2 Comprehensive imaging of the human heart can be performed with identical techniques. Molecular MRI thus offers the potential for complete anatomic, functional, metabolic, and molecular imaging with a single modality from bench to bedside.The advantages of an MRI-based approach to molecular imaging reflect the general attributes of the technique. MRI is noninvasive, tomographic, nonionizing, and able to generate images with high spatial resolution and excellent soft tissue contrast. In the initial portion of the present review, the technology that underlies molecular MRI agents is reviewed. The application of these agents to the imaging of myocardial disease, atherosclerosis, and stem cell therapy in the heart is then discussed. Finally, the potential of multispectral and hybrid imaging techniques is explored.Basic ConsiderationsImaging AgentsChelates of the paramagnetic metal gadolinium have been used as extracellular MR contrast agents for more than a decade. The detection threshold of these chelates is in the micromolar range and thus significantly superior to the millimolar detection limit of iodinated contrast agents. However, because many molecular targets of interest in the cardiovascular system are expressed in the low nanomolar range, the detection sensitivity of routinely used gadolinium chelates is, with rare exceptions, inadequate for molecular MRI. Conventional extracellular gadolinium chelates also have extremely short intravascular half-lives, which limits their utility for most molecular imaging applications.Several novel gadolinium constructs have thus been developed to address these limitations. These include gadolinium chelates with a strong affinity for albumin (MS-325, Epix Pharmaceuticals, Lexington, Mass.),5 gadolinium-containing high-density lipoprotein–like nanoparticles,6,7 gadolinium-containing micelles,8 and gadolinium-containing liposomes.9–11 In addition to longer intravascular half-lives, these novel gadolinium constructs also have higher longitudinal relaxivities (R1). The relaxivity of an MR contrast agent reflects its ability to interact with adjacent protons and strongly influences its detectability. The higher the R1 of an agent, the brighter tissue in its vicinity becomes, whereas the higher the transverse relaxivity (R2), the darker the tissue becomes. The R1 of most clinically approved gadolinium chelates is 4 s−1mM−1.12 The R1 values of the novel gadolinium constructs mentioned above, however, tend to range from 10 to 20 s−1mM−1,7,10 and in the case of some micelles even twice that.8Magnetic iron oxide nanoparticles (MNP) constitute another large class of molecular MRI agents and are based on the ability of these superparamagnetic nanoparticles to modulate the uniformity of a magnetic field.12,13 MNPs have a central core of iron oxide, which measures 3 to 5 nm in diameter surrounded by a dextran, starch, or polymer coat.14,15 A citrate-coated iron oxide nanoparticle has also recently been developed and used as a blood pool agent.16 Selected MNPs have been used extensively in the clinical arena to image the liver and lymphatic system,17 and their established safety record thus makes them a highly appealing platform for molecular MRI. A selected list of representative MNPs is provided in the Table. Selected Superparamagnetic Iron Oxide NanoparticlesCommentShort circulating Ferumoxides (Feridex)Approved liver imaging agent Ferrixan (Resovist)Approved liver imaging agentLong circulating Ferumoxtran (Combidex, AMI 227)Completed phase 3 trials Ferumoxytol (AMI 228)Studied for iron replacement prescription Monocrystalline iron oxide (MION-47)Experimental nanoparticle highly similar to Ferumoxtran Monocrystalline iron oxide (MION-48)Experimental nanoparticle with extremely high transverse relaxivity (R2) Cross-linked iron oxide (CLIO)Experimental nanoparticle developed for targeted imaging Very small superparamagnetic iron oxides (VSOP)Citrate-coated iron oxide nanoparticleThe first generation of MNPs, such as Feridex (Advanced Magnetics, Cambridge, Mass.), contained thin dextran coats and had the propensity to form aggregates in vivo that were rapidly cleared from the bloodstream. Subsequent MNPs have been synthesized with more extensive polymer coatings and remain monodisperse.14 The term monodisperse iron oxide (MION) is thus often applied to these agents. A highly stabilized and cross-linked derivative of MION, known as CLIO, has recently been developed for targeted molecular imaging applications.15,18 CLIO is also aminated, which allows a large variety of ligands to be conjugated to the nanoparticle with relative ease and a high degree of stability. Near infrared fluorochromes, for instance, can be attached to the amine groups on the probe to form a dual-modality magnetofluorescent nanoparticle.19,20 In addition, many copies of the targeting ligand can subsequently be attached to the CLIO-fluorochrome conjugate to form a multivalent (>1 targeting ligand) magnetofluorescent nanoparticle. Examples of 2 such recently used ligands include annexin for apoptosis imaging20,21 and a peptide specific for the vascular cell adhesion molecule 1 (VCAM-1).22,23Intravenously injected MNPs are eventually removed from the circulation by the reticuloendothelial system. The blood half-life of MION and CLIO in humans is 24 hours, and in mice it is 11 hours.24 The small size (approximately 30 nm in diameter) and long circulation half-lives of these agents allow them to penetrate tissues of interest such as atherosclerotic plaques25,26 or the interstitial space of injured pancreas and myocardium.27,28 In addition, the high relaxivities of these probes allow them to detect sparsely expressed targets, such as VCAM-1, with adequate sensitivity. The R1 of MION-47 at 0.5 Tesla is 19 s−1mM−1, whereas its R2 is approximately 50 s−1mM−1.15 The R2 value of CLIO and other more recently developed iron oxides, however, can reach 150 s−1mM−1.29Strategies for Targeted ImagingAn MR contrast agent can be targeted to a moiety on the surface of a cell through 1 of 2 mechanisms. The first involves the attachment to the nanoparticle of a ligand directed against a known target on the cell surface, such as αvβ3 integrin,11,30 phosphatidylserine,20,31 or VCAM-1.22,23 The second approach involves modification of the nanoparticle surface with small molecules to modulate its uptake.32,33 In either scenario the use of phage and chemical screening libraries plays an increasingly important role in probe discovery.33,34 Phage display, for instance, has been used to identify peptides specific for the adhesion molecule VCAM-1.22,35 High-throughput screening of a library of surface-modified CLIO nanoparticles has revealed agents that are highly specific for either resting or activated macrophages.32 Probes may thus be targeted not only to cell type but also to cell state.The earliest targeted MR probes consisted of antibody ligands conjugated to the MR contrast agent.36 Subsequent probes have used antibody fragments,37,38 small proteins,20,21 peptides,23,30 or small molecules,32 usually in a multivalent fashion to enhance probe sensitivity.39 The size and physical properties of certain MNPs, such CLIO, also promote cellular internalization after ligand binding to an appropriate receptor, such as VCAM-1.22,29 The subsequent trapping and compartmentalization of the internalized nanoparticles within lysosomes produces strong biological amplification of the signal in a manner analogous to that of a magnetic relaxation switch,40 described below. This process plays a significant role in the enhancement of the sensitivity of the agent for a sparsely expressed target such as VCAM-1.The stability and nonionizing nature of magnetofluorescent imaging agents allows probe discovery and development to be performed in a highly rigorous and rationalized approach. The presence of a fluorochrome on the probe allows high-throughput screening, flow cytometry, and fluorescence microscopy to be performed in vitro. In addition, ex vivo imaging of probe biodistribution can be performed with fluorescence reflectance imaging and fluorescence microscopy with higher throughput and less expense than MRI. In the final step of the process, in vivo imaging of the validated probe can be performed by MRI. An example of this approach that highlights the study of atherosclerotic plaque inflammation is demonstrated in Figure 2. Download figureDownload PowerPointFigure 2. Development of targeted magnetofluorescent nanoparticles. The discovery of targeting ligands, such as peptides to VCAM-1, is occurring increasingly with phage display and other high-throughput screening techniques. Fluorescence microscopy of a VCAM-1–targeted probe on untreated endothelial cells (A) and cells preincubated with soluble VCAM-1 (B) confirms probe specificity.22 C, Surface modification of magnetofluorescent nanoparticles with small molecules can also introduce target specificity. Constructs with higher (CLIO-NH2) and lower affinity (CLIO-SIA) for macrophages, as well as specificity for activated (CLIO-Gly) and resting macrophages (CLIO-Bentri) have been produced with this technique.32 The in vivo biodistribution and local accumulation of a magnetofluorescent probe can be determined by ex vivo fluorescence imaging. The accumulation of CLIO-NH2 in cellular elements of atherosclerotic plaques in an ApoE−/− mouse is confirmed by fluorescence reflectance imaging (D) and fluorescence microscopy and histology (E through G).26 In vivo MRI of the probe is performed in the final step of the process. Probe accumulation is not seen in the aorta of a control mouse (H), but is clearly seen (arrow) in the aortic arch of an ApoE−/− mouse injected with CLIO-Cy5.5 (I).26MR-Detectable Nanoswitches and BiosensorsTargeted molecular MR contrast agents are designed to image targets with a fairly constant level of expression during image acquisition. However, another class of magnetic nanoparticles, designed specifically to image dynamic events, has recently been described.40,41 These agents, termed magnetic relaxation switches, consist of MNPs that undergo reversible assembly and disassembly in the presence of a specific enzyme or chemical compound. The change in size of the nanoassembly produces a change in R2, which can then be detected by T2-weighted MRI.40,41 Magnetic relaxation switches have previously been developed to detect proteases, oligonucleotides, viral particles, and enantiomeric impurities,40–43 and could be synthesized to detect a wide variety of diagnostic markers used in clinical cardiology. One such potential switch could be designed to detect troponin, brain natriuretic peptide, and C-reactive protein levels in multiplexed format and in whole blood. This could potentially allow point-of-care testing with a bench-top relaxometer to be performed more rapidly and reliably than is currently possible.Magnetic relaxation switches have also been used to determine the concentration of analytes such as glucose and calcium.44,45 A construct that consists of CLIO-glucose and concavalin was able to accurately determine glucose concentration over a clinically meaningful range (Figure 3).44 The mechanism of action of the switch is described in Figure 3. The ability of this switch to accurately measure glucose concentration across a semipermeable membrane raises the possibility of its use as an implantable biosensor in the future.44 It should further be possible for a library of biosensors to be included within a membrane,33 which would allow a panel of cardiovascular metabolites to be sensed continuously and noninvasively by MRI in vivo. Download figureDownload PowerPointFigure 3. Magnetic nanosensing of analytes in solution. A and C, in the presence of low glucose concentrations, the CLIO-glucose nanoparticles bind to concavalin-A and form clusters. B and D, In the presence of high glucose concentrations, CLIO-glucose is displaced from concavalin, which causes the nanoswitch to disassemble. E through G, Changes in glucose concentration can be sensed with a high degree of accuracy by detection of changes in the transverse relaxation time (T2) of the system, which are induced by assembly or disassembly of the nanoswitch. ConA indicates concavalin-A; Glu, glucose.44Enzyme-Activatable ProbesThe concept of enzyme-mediated nanoparticle aggregation has also been extended to novel gadolinium conjugates.46,47 A gadolinium-serotonin chelate, able to sense myeloperoxidase activity, has been developed on the basis of this concept.48 When oxidized by myeloperoxidase, the peptide serotonin forms oligomers with a significantly higher R1 than the parent compound.48 These high-relaxivity oligomers also undergo protein binding, which further increases their R1 (Figure 4). The presence of myeloperoxidase in a mouse model of myositis could be imaged in vivo with this probe, as shown in Figure 4.48 Although further study will be needed, it is possible that myeloperoxidase activity in the myocardium and atherosclerotic plaques will be able to be imaged in vivo with this probe. Download figureDownload PowerPointFigure 4. In vivo MRI of myeloperoxidase activity in mice.48 A, Exposure of the gadolinium-serotonin chelate to myeloperoxidase causes it to undergo oligomerization and protein binding. The protein-bound oligomers have a higher R1 than the parent compound. B, Human myeloperoxidase embedded into a matrix gel and implanted into the right flank of a mouse is able to activate the gadolinium-serotonin probe, whereas an implanted matrix gel without myeloperoxidase (left flank) does not. C, A transient increase in signal intensity (arrow) is seen when gadolinium–diethylenetriamene pentaacetate is injected into a mouse with myositis. D, A sustained increase in signal intensity is seen when the gadolinium-serotonin chelate is used. MPO indicates myeloperoxidase; Gd, gadolinium.Clinical ApplicationsMyocardial InjuryThe hyperacute phase of myocardial injury is characterized by increased capillary permeability and hyperemia. The wash-in kinetics of MNPs, which are normally confined to the intravascular space, can thus be used to demarcate the area of myocardium at risk.28 In the absence of active ligand binding, however, these MNPs are subsequently washed out of acutely injured myocardium, which creates suitable conditions for targeted imaging.21,37 The retention of MNPs in the myocardium during the acute phase of myocardial injury is thus likely to reflect active ligand binding.Several important biological processes occur during acute myocardial injury, such as cardiomyocyte apoptosis, cardiomyocyte necrosis, and free radical release. Annexin V is a protein that binds to phosphatidylserine on the surface of apoptotic cells,49 and pioneering work has previously been done with a radiolabeled annexin probe in patients with acute coronary syndromes50 and cardiac transplant rejection.51 The advantages of an MR-based approach to apoptosis imaging, however, include the ability to acquire high-resolution images of the process and correlate regional probe distribution with indices of myocardial function, perfusion, and viability.The imaging of cardiomyocyte apoptosis by in vivo MRI has recently been performed in a mouse model of transient coronary ligation.21 No significant changes were seen in myocardial signal intensity when mice were injected with an unlabeled control probe. However, as shown in Figure 5, injection of an identical dose of the annexin-labeled probe AnxCLIO-Cy5.5 produced significant negative contrast enhancement in the injured myocardium.21 A small (40 nm in diameter) annexin-coated gadolinium-containing liposome has also recently been used to successfully image cardiomyocyte apoptosis in the isolated perfused rat heart ex vivo (Figure 5).52 The utility of this construct for in vivo imaging, however, will require further study. Download figureDownload PowerPointFigure 5. Molecular MRI of myocardial injury. A, Superparamagnetic MION does not accumulate in the transplanted heart of a rat treated with cyclosporine. B, Significant signal loss from monodisperse iron oxide accumulation, however, is seen in the transplanted heart of an untreated rat. Adapted from Kanno et al55 with permission of the publisher. Copyright © 2001, The American Heart Association, Inc. C, Imaging of cardiomyocyte necrosis in a rat heart ex vivo with an antimyosin-labeled monodisperse iron oxide probe.37 The accumulation of the probe in the distribution of the ligated coronary artery produces negative contrast enhancement. D, Imaging of cardiomyocyte apoptosis with the nanoparticle AnxCLIO-Cy5.5 in the mouse heart in vivo.21 Negative contrast enhancement (arrows) is seen in the anterior wall of the left ventricle after transient coronary artery occlusion, which is caused by the uptake of the probe by apoptotic cardiomyocytes. No changes in signal intensity were seen with the injection of an equivalent dose of the unlabeled probe, CLIO-Cy5.5. E, Uptake of a gadolinium-annexin construct in an isolated perfused rat heart model ex vivo.52 Probe accumulation is seen after the creation of transient ischemia.Apoptosis is the dominant form of cell loss during the first few hours after complete coronary artery occlusion,53 after which necrosis predominates. Cardiomyocyte necrosis has been imaged by MRI in the rat heart ex vivo with an antimyosin antibody conjugated to MION (Figure 5).37 The use of this probe in conjunction with annexin-based probes could thus provide powerful insights into the pathogenesis of cell death during acute myocardial injury.Several conditions in the myocardium, such as healing infarcts and transplant rejection, are characterized by macrophage infiltration and can be imaged with the use of macrophage-avid MNPs. Surface modification of the nanoparticle can also refine the specificity of the MNP for either resting or activated macrophages.32 Long-circulating MNPs have been shown to accumulate in several models of tissue inflammation27,54 and have already been used to successfully image transplant rejection in a rat model.55Atherosclerosis and Vascular DiseaseMolecular MRI approaches to the imaging of atherosclerosis have focused on the detection of plaque lipid content, plaque inflammation, plaque thrombosis, and plaque angiogenesis.56 Gadofluorine is a novel chelate of gadolinium, which is more lipophilic and has a longer circulation half-life than conventional chelates. This compound has been shown in a rabbit model to accumulate preferentially in lipid-rich atherosclerotic plaques (Figure 6).57,58 A liposome that contains gadolinium and is targeted to the αvβ3 integrin has also been used in a rabbit model of atherosclerosis to image plaque angiogenesis (Figure 6).11 Furthermore, incorporation of the antiangiogenic agent fumagillin into the liposome was shown by MRI to decrease subsequent uptake of the probe (Figure 6).59 The concept of using a targeted magnetic nanoparticle in both a diagnostic and therapeutic capacity has thus been demonstrated. Download figureDownload PowerPointFigure 6. Imaging of atherosclerosis with paramagnetic gadolinium-based probes. Detection of lipid-rich atherosclerotic plaques can be accomplished with agents such as gadofluorine (A) and a high-density lipoprotein–like nanoparticle that contains gadolinium (B); A is reproduced with permission from Frias et al.6 Copyright © 2004, American Chemical Society. B is reproduced from Sirol et al,58 with permission of the publisher. Copyright © 2004, the American Heart Association, Inc. C and D, Angiogenesis in atherosclerotic plaques has been detected with a liposome that contains gadolinium targeted to the αvβ3 integrin. Incorporation of the antiangiogenic agent fumagillin into the liposome results in a significant decrease in plaque neovascularization (E), which is not seen when the agent is absent in the liposome (F); reproduced from Winter et al.59 with permission of the publisher. Copyright © 2006, The American Heart Association, Inc. G, Imaging of plaque thrombosis in vivo with a fibrin-targeted gadolinium chelate; reproduced from Botnar et al,62 with permission of the publisher. Copyright © 2004, The American Heart Association, Inc.High-density lipoprotein–like nanoparticles that contain gadolinium have also been shown to accumulate in atherosclerotic plaques (Figure 6).6,7 Several variants of these nanoparticles have been synthesized,6,7 and their rate of uptake by plaques in apolipoprotein E–deficient (ApoE−/−) mice seems to be determined by the lipid and macrophage content of the plaque. Plaques rich in macrophages tended to take up the probe more quickly than those with a low macrophage content.7 Plaque macrophage content has also been imaged ex vivo in explanted aortas from ApoE−/− mice with a micelle that contains gadolinium and is decorated with an antibody to the macrophage scavenger receptor.8The largest experience in the imaging of plaque macrophage content, however, has been with MNPs.56 Long-circulating MNPs are able to penetrate an atherosclerotic plaque and are then taken up by its cellular components. Plaque inflammation has been imaged with MNPs in mice,26 large animal models,60 and in human carotid arteries in vivo.25,61 The use of the MNP CLIO-Cy5.5 in ApoE−/− mice showed that although the majority (65%) of CLIO-Cy5.5 within the plaque was taken up by macrophages, activated smooth muscle and endothelial cells also accumulated the probe.26 In large animal models and humans, a good correlation between in vivo visualization of the MNP and the histological presence of plaque macrophages has also consistently been found.25,60,61Two gadolinium-based probes have been developed to image fibrin and detect thromboses and vulnerable atherosclerotic plaques. A fibrin-specific peptide has been conjugated to a chelate that contains gadolinium to yield a low molecular weight probe.62–65 The high levels of fibrin in thrombi allow high target to background ratios to be obtained with this probe, and both acute and subacute thrombi have thus been successfully imaged in vivo in a variety of large animal models (Figure 6).62–65 A fibrin-targeted liposome that contains gadolinium and is able to image thrombosis in a dog model in vivo by MRI38 has also been developed.9One of the principle aims of molecular imaging is the detection of early disease. Thus, significant interest exists in the development of probes to detect expression of the adhesion molecule VCAM-1 on vascular endothelium. Several generations of VCAM-1–targeted MNPs have now been developed. The first of these agents used a cyclic peptide to bind to VCAM-1,35 whereas the most recent used a phage-derived linear peptide.22,23 The experience with the linear peptide-based probe, however, is perhaps the most illustrative of the potential of molecular MRI. VCAM-1 expression could be successfully imaged in the aortic roots of ApoE−/− mice in vivo with this agent (Figure 7).23 In addition, the beneficial effect of statin therapy on VCAM-1 expression could be documented in vivo by demonstration of decreased accumulation of the probe in the aortic roots of statin treated mice (Figure 7).23 This VCAM-1–sensing MNP thus not only demonstrated adequate sensitivity to detect a sparsely expressed molecular marker early in the disease process, but also adequate dynamic range to detect a treatment effect. Download figureDownload PowerPointFigure 7. In vivo imaging of VCAM-1 expression in ApoE−/− mice with the VCAM-1 sensing probe VINP-28.23 A, Gradient echo MR image of the long axis of the left ventricle and thoracic aorta. The short-axis plane through the aortic root is shown by the dashed red line. Short-axis images of the aortic root before (B) and after (C) the injection of VINP-28. Significant accumulation of the probe, consistent with VCAM-1 expression, is seen in the plaque-rich aortic root. VCAM-1 expression by in vivo MRI in the aortic root of a cholesterol-fed ApoE−/− mouse (D) is significantly higher than in a statin-treated ApoE−/− mouse fed the same diet (E); HCD indicates high-cholesterol diet. Ex vivo fluorescence images of the aortic root confirm higher probe accumulation in the untreated mouse (F) than the statin-treated mouse (G). Probe accumulation by fluorescence microscopy (H) correlates well with VCAM-1 expression by immunohistochemistry (I).Stem Cell ImagingThe MNP Feridex has been used to label and image stem cells injected directly into the myocardium (Figure 8).66,67 However, when cells colabeled with Feridex and 111indium-oxine were injected peripherally, homing to the heart could be detected only by single-photon emission computed tomography and not by MRI (Figure 9).68 This is in contrast to the experience in the brain, where even single iron oxide–labeled cells have been successfully detected.69,70 At present, therefore, the main utility of imaging iron oxide–labeled cells in the heart lies in its ability to precisely delineate the infarct, guide the intramyocardial injection of the cells, and track their movement over time.66,67Download figureDownload PowerPointFigure 8. MR imaging of stem cell therapy. A and B, MRI of iron oxide–labeled mesenchymal stem cells injected directly into the myocardium of a pig. The labeled stem cells produce strong negative contrast enhancement on both gradient echo (A) and delayed enhancement (B) images, which allows their location relative to the infarct to be precisely determined; reproduced from Kraitchman et al,66 with permission of the publisher. Copyright © 2003, The American Heart Association, Inc. C through G, MRI-based reporter gene techniques to potentially determine stem cell survival. C, expression by implanted tumor cells of an engineered human transferrin receptor on their cell surface;73 cells that express the receptor undergo a marked increased in transverse relaxivity (R2) after the injection of a magnetic iron oxide nanoparticle conjugated to transferrin. D, adenoviral MRI reporter that encodes for the synthesis of ferritin from endogenous iron stores, which can then be detected by MRI (arrow); reproduced by permission from Macmillan Publishers Ltd: Nature Medicine,75 copyright © 2005. E, reporter gene that encodes for a biotinylated surface receptor (BAP-TM).74 Tumor cells that express the receptor have a significant increase in transverse relaxivity (decrease in T2) after systemic injection of a CLIO-streptavidin conjugate. F and G, cells in a Xenopus embryo that express the enzyme galactosidase are able to activate a cleavable gadolinium construct, which produces a local increase in MR signal intensity; adapted by permission from Macmillan Publishers Ltd: Nature Biotechnology,72 copyright © 2000.Download figureDownload PowerPointFigure 9. Potential value of hybrid imaging in molecular MRI. A through C, Single-photon emission computed tomographic imaging of the transglutaminase Factor XIII in a healing myocardial infarct. Autoradiography of a Factor XIII–targeted 111indium probe shows a local increase in activity in the infarcted myocardium, which correlates well with the zone of hypocontractile myocardium by cine MRI (B) and TTC staining (C) of the infarcted tissue. D," @default.
• W2083606656 created "2016-06-24" @default.
• W2083606656 creator A5006765223 @default.
• W2083606656 creator A5067255019 @default.
• W2083606656 creator A5078805078 @default.
• W2083606656 date "2007-04-17" @default.
• W2083606656 modified "2023-10-04" @default.
• W2083606656 title "Molecular Magnetic Resonance Imaging in Cardiovascular Medicine" @default.
• W2083606656 cites W1492726842 @default.
• W2083606656 cites W1501982791 @default.
• W2083606656 cites W1510613202 @default.
• W2083606656 cites W1967727706 @default.
• W2083606656 cites W1971686124 @default.
• W2083606656 cites W1984055074 @default.
• W2083606656 cites W1988072585 @default.
• W2083606656 cites W1993157780 @default.
• W2083606656 cites W1994283713 @default.
• W2083606656 cites W2004730560 @default.
• W2083606656 cites W2006224145 @default.
• W2083606656 cites W2007341156 @default.
• W2083606656 cites W2013228340 @default.
• W2083606656 cites W2014945829 @default.
• W2083606656 cites W2016524717 @default.
• W2083606656 cites W2019430054 @default.
• W2083606656 cites W2020336311 @default.
• W2083606656 cites W2025244200 @default.
• W2083606656 cites W2036488510 @default.
• W2083606656 cites W2039963413 @default.
• W2083606656 cites W2041904666 @default.
• W2083606656 cites W2047276981 @default.
• W2083606656 cites W2055696013 @default.
• W2083606656 cites W2058626646 @default.
• W2083606656 cites W2059246878 @default.
• W2083606656 cites W2064313651 @default.
• W2083606656 cites W2064582130 @default.
• W2083606656 cites W2070931231 @default.
• W2083606656 cites W2075048068 @default.
• W2083606656 cites W2076212755 @default.
• W2083606656 cites W2085736171 @default.
• W2083606656 cites W2088556738 @default.
• W2083606656 cites W2088848593 @default.
• W2083606656 cites W2089470527 @default.
• W2083606656 cites W2092045871 @default.
• W2083606656 cites W2093718909 @default.
• W2083606656 cites W2099365062 @default.
• W2083606656 cites W2101037111 @default.
• W2083606656 cites W2101681003 @default.
• W2083606656 cites W2108524724 @default.
• W2083606656 cites W2112285684 @default.
• W2083606656 cites W2113580829 @default.
• W2083606656 cites W2114064853 @default.
• W2083606656 cites W2116810900 @default.
• W2083606656 cites W2118473182 @default.
• W2083606656 cites W2119161500 @default.
• W2083606656 cites W2120563506 @default.
• W2083606656 cites W2120666169 @default.
• W2083606656 cites W2127194007 @default.
• W2083606656 cites W2127457668 @default.
• W2083606656 cites W2128113402 @default.
• W2083606656 cites W2129445703 @default.
• W2083606656 cites W2129811318 @default.
• W2083606656 cites W2130796239 @default.
• W2083606656 cites W2132406310 @default.
• W2083606656 cites W2132746436 @default.
• W2083606656 cites W2134634078 @default.
• W2083606656 cites W2140611255 @default.
• W2083606656 cites W2149545411 @default.
• W2083606656 cites W2149826221 @default.
• W2083606656 cites W2150953486 @default.
• W2083606656 cites W2151354541 @default.
• W2083606656 cites W2155976768 @default.
• W2083606656 cites W2158845879 @default.
• W2083606656 cites W2159412453 @default.
• W2083606656 cites W2159653257 @default.
• W2083606656 cites W2160271782 @default.
• W2083606656 cites W2164564532 @default.
• W2083606656 cites W2167946663 @default.
• W2083606656 cites W2170678073 @default.
• W2083606656 cites W2171882555 @default.
• W2083606656 cites W2186448008 @default.
• W2083606656 cites W2189019768 @default.
• W2083606656 cites W2318269276 @default.
• W2083606656 cites W2321341340 @default.
• W2083606656 cites W47345933 @default.
• W2083606656 doi "https://doi.org/10.1161/circulationaha.106.658930" @default.
• W2083606656 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17438163" @default.
• W2083606656 hasPublicationYear "2007" @default.
• W2083606656 type Work @default.
• W2083606656 sameAs 2083606656 @default.
• W2083606656 citedByCount "130" @default.
• W2083606656 countsByYear W20836066562012 @default.
• W2083606656 countsByYear W20836066562013 @default.
• W2083606656 countsByYear W20836066562014 @default.
• W2083606656 countsByYear W20836066562015 @default.
• W2083606656 countsByYear W20836066562016 @default.
• W2083606656 countsByYear W20836066562017 @default.
• W2083606656 countsByYear W20836066562018 @default.
• W2083606656 countsByYear W20836066562019 @default.

• next